Question explored with the scientific record
What is good for prostate
The short version: for an enlarged prostate causing bothersome symptoms, a one-time water vapor procedure (Rezūm) outperforms daily pills on symptom relief and progression, with fewer side effects, over at least three years.
The evidence here compares several approaches for benign prostatic hyperplasia (BPH), which is not cancer. The most direct head-to-head data comes from a 2018 study that matched Rezūm thermal therapy patients to men from the MTOPS drug trial [3]. Over three years, the procedure group had a clinical progression rate of 0.3 per 100 person-years, compared to 1.5 to 1.7 for doxazosin, finasteride, or their combination [3]. That is roughly a five-fold lower rate. Symptom scores (I-PSS) improved by about 5 points more with Rezūm than with finasteride at three months [3].
The drug studies themselves show modest effects. Alpha-blockers like doxazosin improve symptoms by about 6 points on a 35-point scale, but come with dizziness, fatigue, and low blood pressure in a notable minority [2, 6]. Finasteride and dutasteride shrink the prostate by roughly 20% over a year, but cause sexual side effects and take months to work [4, 25]. A 1996 trial found the saw palmetto extract Permixon matched finasteride on symptom relief with fewer sexual side effects, though it did not shrink the prostate as much [4].
Surgical options like TURP or HoLEP give the largest and most durable symptom improvement, but carry risks of bleeding, retrograde ejaculation, and longer recovery [8, 11]. For moderate symptoms, the one-time water vapor procedure sits between drugs and surgery: better than drugs, less invasive than cutting.
| Treatment | Symptom improvement (I-PSS change) | Clinical progression (per 100 person-years) | Key trade-offs |
|---|---|---|---|
| Rezūm (one-time) | -11 points at 3 years [10] | 0.3 [3] | Temporary dysuria, hematuria; preserves sexual function |
| Doxazosin (daily) | -6 points [2] | 1.7 [3] | Dizziness, fatigue, hypotension |
| Finasteride (daily) | -5 points [2] | 1.5 [3] | Sexual dysfunction, 6-month delay |
| Permixon (saw palmetto) | -6 points [4] | Not reported | Fewer sexual side effects than finasteride |
My call: for a man with moderate BPH symptoms who wants to avoid daily pills and their side effects, the one-time water vapor procedure has the best evidence here for durable relief with low risk. Confidence is moderate — the comparison to drugs is from a cohort study, not a randomized head-to-head trial, and the long-term data beyond three years is thin.
Sources used 8
-
The clinical efficacy and tolerability of doxazosin standard and gastrointestinal therapeutic system for benign prostatic hyperplasia
This article reviews and synthesizes randomized trials comparing doxazosin standard and the extended-release gastrointestinal therapeutic system (GITS) formulations for benign prostatic hyperplasia (BPH), showing similar efficacy in symptom relief with GITS offering better toler…
DOI: 10.1111/j.1464-410X.2005.05342.x -
Three-Year Treatment Outcomes of Water Vapor Thermal Therapy Compared to Doxazosin, Finasteride and Combination Drug Therapy in Men with Benign Prostatic Hyperplasia: Cohort Data from the MTOPS Trial
This study evaluates the long-term outcomes of a one-time water vapor thermal therapy procedure compared to daily medical therapy for lower urinary tract symptoms due to benign prostatic hyperplasia, finding that thermal therapy provides more effective and durable symptom relief…
DOI: 10.1016/j.juro.2018.02.3088 -
Comparison of phytotherapy (Permixon®) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients
This study compares the efficacy of the phytotherapy Permixon@ and the 5a-reductase inhibitor finasteride in treating benign prostatic hyperplasia (BPH) in 1,098 men, finding both treatments similarly effective in symptom relief but with differing impacts on prostate volume and …
DOI: 10.1002/(sici)1097-0045(199610)29:4<231::aid-pros4>3.0.co;2-e -
Clinical Uroselectivity: A 3-Year Follow-Up in General Practice
An open-label, 3-year follow-up in general practice assessing the long-term uroselectivity, symptom relief, health-related quality of life, and safety of alfuzosin for benign prostatic hyperplasia in a large, real-world patient cohort.
DOI: 10.1159/000052231 -
Comparative Outcomes of Open Prostatectomy and Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia
Transurethral Resection of the Prostate (TURP) provides faster recovery and better short-term urinary symptom relief with less postoperative pain and shorter hospital stay than Open Prostatectomy (OP) in benign prostatic hyperplasia, though OP remains an option for very large pr…
DOI: 10.54393/pjhs.v5i12.1991 -
Three-Year Outcomes of the Prospective, Randomized Controlled Rezūm System Study: Convective Radiofrequency Thermal Therapy for Treatment of Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia
Convective RF water vapor therapy provides rapid, durable relief of LUTS/BPH with preserved sexual function over 3 years in a multicenter randomized trial, with a low retreatment rate and favorable safety profile.
DOI: 10.1016/j.urology.2017.10.023 -
A Randomized Trial Comparing Holmium Laser Enucleation of the Prostate with Transurethral Resection of the Prostate for the Treatment of Bladder Outlet Obstruction Secondary to Benign Prostatic Hyperplasia in Large Glands (40 to 200 Grams)
This study compares the efficacy and safety of Holmium Laser Enucleation of the Prostate (HoLEP) versus Transurethral Resection of the Prostate (TURP) for treating bladder outlet obstruction due to benign prostatic hyperplasia in patients with large prostate glands, finding HoLE…
DOI: 10.1097/01.ju.0000086948.55973.00 -
Medical Treatment of the Benign Prostatic Hyperplasia
A comprehensive narrative review of pharmacological treatments for benign prostatic hyperplasia (BPH), detailing mechanisms, efficacy, and safety of alpha-blockers, 5-alpha-reductase inhibitors, antiandrogen/hormonal therapies, and combination regimens, with implications for ini…
DOI: 10.5124/jkma.2004.47.2.163